CDA | Evidence Driven
CDA | Evidence Driven

Icatibant Implementation Advice Panel

Details

Files
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0097-000 - SX0849-000

Canada’s Drug Agency is convening an implementation advice panel to advise the drug programs on funding criteria for icatibant for hereditary angioedema (HAE) with normal C1-inhibitor function (HAE nC1-INH), also known as type III HAE.

Call for feedback
Call for feedback:
Feedback Due By
Feedback Due By:
Consultation document
Consultation document: Draft Report
Product Line
Product Line: Health Technology Review
Project Number
Project Number: HC0097-000 - SX0849-000
Submit Feedback
 

Files

Draft Report View PDF
Proposed Scope View PDF
Last Updated : October 31, 2024